Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Receivables: 2019-2024

Historic Change in Receivables for Zevra Therapeutics (ZVRA) over the last 6 years, with Dec 2024 value amounting to -$6.9 million.

  • Zevra Therapeutics' Change in Receivables fell 17.46% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 489.75%. This contributed to the annual value of -$6.9 million for FY2024, which is 175.66% down from last year.
  • Latest data reveals that Zevra Therapeutics reported Change in Receivables of -$6.9 million as of FY2024, which was down 175.66% from $9.1 million recorded in FY2023.
  • Zevra Therapeutics' Change in Receivables' 5-year high stood at $9.1 million during FY2023, with a 5-year trough of -$6.9 million in FY2024.
  • Moreover, its 3-year median value for Change in Receivables was $6.8 million (2022), whereas its average is $3.0 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first slumped by 247.20% in 2021, then skyrocketed by 744.34% in 2022.
  • Zevra Therapeutics' Change in Receivables (Yearly) stood at $714,000 in 2020, then slumped by 247.20% to -$1.1 million in 2021, then spiked by 744.34% to $6.8 million in 2022, then spiked by 34.05% to $9.1 million in 2023, then crashed by 175.66% to -$6.9 million in 2024.